George Fountzilas

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

C. Focan, S. M. Steinberg, M Blichert-Toft et al. · PubMed · 1998 · 2.2K citations

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Retrospective Consortium Analysis, Medicine, Pathology +5

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

Fergus J. Couch, Steven N. Hart, Priyanka Sharma et al. · Journal of Clinical Oncology · 2014 · 670 citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon

Helen Gogas, J. Ioannovich, Urania Dafni et al. · New England Journal of Medicine · 2006 · 560 citations